ImmunityBio shared a posted on LinkedIn:
“The European Commission has granted conditional marketing authorization for ANKTIVA (nogapendekin alfa inbakicept) in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
This decision broadens availability across 33 European countries and marks meaningful progress for patients facing limited treatment options in this setting. Learn more.”
Proceed to watch the video attached to the post.
Other articles about Bladder Cancer on OncoDaily.